11 reports of this reaction
5.2% of all ACETAMINOPHEN 325 MG reports
#1 most reported adverse reaction
INFUSION RELATED REACTION is the #1 most commonly reported adverse reaction for ACETAMINOPHEN 325 MG, manufactured by Ulai Health LLC. There are 11 FDA adverse event reports linking ACETAMINOPHEN 325 MG to INFUSION RELATED REACTION. This represents approximately 5.2% of all 211 adverse event reports for this drug.
Patients taking ACETAMINOPHEN 325 MG who experience infusion related reaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION RELATED REACTION is moderately reported among ACETAMINOPHEN 325 MG users, representing a notable but not dominant share of adverse events.
In addition to infusion related reaction, the following adverse reactions have been reported for ACETAMINOPHEN 325 MG:
The following drugs have also been linked to infusion related reaction in FDA adverse event reports:
INFUSION RELATED REACTION has been reported as an adverse event in 11 FDA reports for ACETAMINOPHEN 325 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION RELATED REACTION accounts for approximately 5.2% of all adverse event reports for ACETAMINOPHEN 325 MG, making it one of the most commonly reported side effect.
If you experience infusion related reaction while taking ACETAMINOPHEN 325 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.